Zydus Lifesciences shares were trading at RS 910.65, rising by 5.80 points or 0.64% from the previous close of RS 904.85 on the BSE. The stock opened at RS 904.80 and touched an intraday high of RS 916.00 and a low of RS 904.25. A total of 3,360 shares changed hands on the counter.

The BSE Group ‘A’ stock with a face value of RS 1 hit a 52-week high of RS 1059.00 on 19-Sep-2025 and a 52-week low of RS 797.05 on 07-Apr-2025. Over the past week, the scrip recorded a high of RS 933.40 and a low of RS 882.00. The company’s current market capitalisation stands at RS 91788.66 crore.

Promoters hold a 75.00% stake in the company, while institutional and non-institutional investors own 18.15% and 6.85%, respectively.

In a key development, the company has received final approval from the United States Food and Drug Administration (USFDA) for Ammonium Lactate Cream, 12% (USRLD: Lac-Hydrin Cream, 12%).

Ammonium lactate cream, 12% is a topical prescription medicine indicated for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris, a hereditary skin condition. The formulation works by enhancing skin hydration and, as an alpha-hydroxy acid, helps reduce itching, soften the skin, and minimise scaling.

The product will be manufactured at the group’s topical manufacturing facility in Changodar, Ahmedabad, and marketed in the US by Viona Pharmaceuticals Inc.. According to IQVIA MAT December 2025 data, the product recorded annual sales of $15 million in the United States.

With this approval, the group now has 430 approvals and has filed 505 ANDAs since initiating the filing process in FY 2003-04.

Zydus Lifesciences, formerly known as Cadila Healthcare, is an integrated pharmaceutical company engaged across the entire value chain, including research, development, manufacturing, marketing, and distribution of pharmaceutical products.